C12N 5/0639
Dendritic cells
Official title: {Dendritic cells, e.g. Langherhans cells in the epidermis}
C12N5/0639 (Dendritic cells) appears on 570 US grants and 1,149 published applications in this corpus.
Search patents in C12N- Granted patents
- 570
- Published applications
- 1,149
- Assignees
- 545
- Inventors
- 1,908
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 2 | 0 |
| 1998 | 4 | 0 |
| 1999 | 7 | 0 |
| 2000 | 5 | 0 |
| 2001 | 8 | 8 |
| 2002 | 7 | 19 |
| 2003 | 8 | 29 |
| 2004 | 3 | 37 |
| 2005 | 8 | 30 |
| 2006 | 5 | 42 |
| 2007 | 5 | 22 |
| 2008 | 7 | 22 |
| 2009 | 9 | 29 |
| 2010 | 18 | 41 |
| 2011 | 17 | 32 |
| 2012 | 23 | 46 |
| 2013 | 31 | 49 |
| 2014 | 33 | 48 |
| 2015 | 21 | 50 |
| 2016 | 32 | 42 |
| 2017 | 34 | 60 |
| 2018 | 37 | 53 |
| 2019 | 34 | 67 |
| 2020 | 30 | 60 |
| 2021 | 36 | 73 |
| 2022 | 28 | 72 |
| 2023 | 30 | 56 |
| 2024 | 33 | 69 |
| 2025 | 27 | 47 |
| 2026 | 28 | 46 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- FOXM1-derived peptide, and vaccine including same29 Sep 2026US 12,747,265 B2Oncotherapy Science, Inc.
- Fixed ratio ex vivo activated mixed lymphocyte products for use in the treatment of cancer22 Sep 2026US 12,742,153 B2Children's National Medical Center
- Trojan circulating tumor cells8 Sep 2026US 12,728,140 B2Astrin Biosciences, Inc.
- Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR)25 Aug 2026US 12,714,745 B2Baylor Research Institute
- Light-induced cellular production of immune functional extracellular vesicles25 Aug 2026US 12,714,751 B2University of Florida Research Foundation, Inc.
- Methods of sensitizing tumors to treatment with immune checkpoint inhibitors8 Oct 2026US 2026/0306658 A1University of Florida Research Foundation, Inc.
- Lymphoid tissues with switchable protein gradients8 Oct 2026US 2026/0308498 A1Georgia Tech Research Corporation
- Composition for inducing dendritic cell differentiation, comprising metal-organic framework, and use thereof8 Oct 2026US 2026/0308523 A1Mediark Inc.
- Compositions comprising and methods of using dendritic cell exosomes8 Oct 2026US 2026/0308524 A1Baylor College of Medicine
- Chemoenzymatic method for the detection of cell-cell proximity interaction and isolation of tumor-specific antigen reactive t cells for immune therapy8 Oct 2026US 2026/0308537 A1The Scripps Research Institute
Most cited
By later US patents
- Immunostimulatory nucleic acid molecules for activating dendritic cells265US 6,429,199 B1University of Iowa Research Foundation · 2002
- Maturation of dendritic cells with immune response modifying compounds206US 6,558,951 B13M Innovative Properties Company · 2003
- Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens124US 5,994,126 AThe Rockefeller University · 1999
- Methods related to immunostimulatory nucleic acid-induced interferon110US 6,949,520 B1Coley Pharmaceutical GmbH · 2005
- Artificial antigen presenting cells and uses therefor105US 7,754,482 B2The Trustees of the University of Pennsylvania · 2010